Previous close | 25.00 |
Open | 25.40 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 25.40 - 25.40 |
52-week range | 24.00 - 39.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts. To skip our analysis of the recent market activity, you can go directly to see the Aggressive Stock Portfolio: 5 Stocks Picked by Analysts. By definition, aggressive stocks are ones that offer higher returns than conservative and relatively […]
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.